Comparative Pharmacology
Head-to-head clinical analysis: FLUORINE F 18 versus PYLARIFY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUORINE F 18 versus PYLARIFY.
FLUORINE F-18 vs PYLARIFY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluorine-18 decays by positron emission, and the emitted positron annihilates with an electron to produce two 511 keV gamma photons. When incorporated into radiopharmaceuticals such as fludeoxyglucose F-18, it accumulates in metabolically active tissues, enabling PET imaging.
Gallium Ga 68 gozetotide is a radioactive diagnostic agent that binds to prostate-specific membrane antigen (PSMA), which is overexpressed on prostate cancer cells. It allows for positron emission tomography (PET) imaging of PSMA-positive lesions.
2-10 mCi (74-370 MBq) intravenous bolus, single administration for PET imaging.
1 mg/kg IV bolus administered once.
None Documented
None Documented
Physiological half-life is 109.7 minutes (1.83 hours) for fluorine-18 decay by positron emission, with a physical half-life of 109.7 minutes. The biological half-life is dependent on the radiolabeled compound; for [18F]FDG, the effective half-life is approximately 3-4 hours.
Terminal elimination half-life of approximately 12.3 hours (range 8-18 hours), supporting once-daily dosing in clinical practice.
Primarily renal; approximately 95% of administered activity is excreted in urine within 6 hours post-injection. Less than 5% is excreted in feces.
Renal (approximately 99% of administered dose as unchanged drug) and fecal (<1%).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical